Exact Sciences (Exact Sciences) Net Margin %

: -7.69% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Exact Sciences's Net Income for the three months ended in Dec. 2023 was $-50 Mil. Exact Sciences's Revenue for the three months ended in Dec. 2023 was $647 Mil. Therefore, Exact Sciences's net margin for the quarter that ended in Dec. 2023 was -7.69%.

The historical rank and industry rank for Exact Sciences's Net Margin % or its related term are showing as below:

EXAS' s Net Margin % Range Over the Past 10 Years
Min: -5564.4 Med: -40.78 Max: -8.17
Current: -8.17

EXAS's Net Margin % is ranked better than
52.21% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.145 vs EXAS: -8.17

Exact Sciences Net Margin % Historical Data

The historical data trend for Exact Sciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

-24.32

-55.22

-33.71

-29.91

-8.17

Exact Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-23.10	-12.31	-13.02	0.13	-7.69

Competitive Comparison

For the Diagnostics & Research subindustry, Exact Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exact Sciences Net Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Net Margin % falls into.

Exact Sciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Exact Sciences's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-204.149	/	2499.766
	=	-8.17 %

Exact Sciences's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-49.766	/	646.885
	=	-7.69 %

Exact Sciences (NAS:EXAS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Exact Sciences Net Margin % Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Sciences (Exact Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (NAS:EXAS) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

EXK:Germany

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.

Executives

Brian Baranick	officer: Gen. Mgr., Precision Oncology	441 CHARMANY DRIVE, MADISON WI 53719
Sarah Condella	officer: SVP, Human Resources	441 CHARMANY DRIVE, MADISON WI 53719
Timothy J Scannell	director	2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Everett Cunningham	officer: Chief Commercial Officer	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeffrey Thomas Elliott	officer: Chief Financial Officer	5505 ENDEAVOR LANE, MADISON WI 53719
James Edward Doyle	director	5505 ENDEAVOR LANE, MADISON WI 53719
James Herriott	officer: General Counsel	5505 ENDEAVOR LANE, MADISON WI 53719
Katherine S Zanotti	director	431 E 9TH STREET, HINSDALE IL 60521
Jacob A Orville	officer: General Manager, New Ventures	5505 ENDEAVOR LANE, MADISON WI 53719
Kevin T Conroy	director, officer: Vice President	5505 ENDEAVOR LANE, MADISON WI 53719
D Scott Coward	officer: SVP and General Counsel	441 CHARMANY DRIVE, MADISON WI 53719
Paul J Clancy	director	C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Graham Peter Lidgard	officer: SVP, Chief Scientific Officer	5505 ENDEAVOR LANE, MADISON WI 53719
Michael S Wyzga	director	RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139
Torsten Hoof	officer: General Manager, International	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063